Cite
THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL
MLA
Arnott, C., et al. The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the Credence Trial. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1259604166&authtype=sso&custid=ns315887.
APA
Arnott, C., Li, J.-W., Cannon, C., Neuen, B., Heerspink, H., Neal, B., Charytan, D., Agarwal, R., Bakris, G., De Zeeuw, D., Greene, T., Levin, A., Pollock, C., Chang, T., Rosenthal, N., Zhang, H., Zinman, B., Perkovic, V., Jardine, M., & Mahaffey, K. (2020). The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the Credence Trial.
Chicago
Arnott, C, J-W Li, Cp Cannon, B Neuen, Hl Heerspink, B Neal, Dm Charytan, et al. 2020. “The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the Credence Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1259604166&authtype=sso&custid=ns315887.